To Your Good Health: Aggressive treatment for Crohn's - Tribune Chronicle -

What To Know

Your doctor is following current guidelines that prioritize treating objective inflammation, not just symptoms. The article emphasizes checking for infection first (for example C. difficile) and then escalating to biologic therapy when endoscopy and CRP show active disease.

Risankizumab (Skyrizi) is named as an IL-23–blocking biologic the physician considers to have a favorable balance of effectiveness and safety; common side effects mentioned include mild respiratory infections, headaches, and joint aches. The piece notes the treatment goal is to prevent long-term complications such as strictures and fistulae.

If you have concerns, discuss with your clinician about confirming no infection, the reasons for escalation, alternative biologic classes, expected monitoring, and how benefits and risks apply to your situation.